Please login to the form below
myelofibrosis
This page shows the latest myelofibrosis news and features for those working in and with pharma, biotech and healthcare.
Daily Brief: Brexit reshuffle brings new health minister, Celgene thalassemia success, Wellcome read to leap into future
The companies are also developing luspatercept for the treatment of myelofibrosis.
Latest news
-
CTI slumps as Servier-partnered lymphoma drug fails
CTI slumps as Servier-partnered lymphoma drug fails. After major setback CTI, has promising myelofibrosis candidate to fall back on. ... If approved, it will compete with Incyte and Novartis' Jakafi (ruxolitinib) in myelofibrosis, which is predicted to
-
Another R&D flop for Incyte, but Jakafi keeps delivering
Jakafi is marketed by Incyte in the US and by Novartis (as Jakavi) in other markets, for polycythemia vera and myelofibrosis. ... after a less-than-optimal FDA approval, and data suggesting that myelofibrosis patients treated with Jakafi may be at
-
Daily Brief
Another drug price sampled was Novartis’myelofibrosis treatment Jakavi. The algorithm judges that a fair price would be $17, 251 per treatment, far below the UK ($59, 760) and US ($90,
-
FDA turns down Celgene’s filing for multiple sclerosis drug
$7bn for Impact Biomedicines to add late-stage candidate fedratinib for myelofibrosis and polycythemia vera.
-
Is acquisitive Celgene now eyeing CAR-T specialist Juno?
inhibitor - fedratinib - in development for myelofibrosis and polycythaemia vera.
More from news
Approximately 8 fully matching, plus 43 partially matching documents found.
Latest Intelligence
-
Deal Watch January 2018
Celgene will pay approximately $1.1bn upfront for Impact and further contingent payments based on regulatory approval for fedratinib in myelofibrosis and other indications could amount to $1.4bn. ... Acquisition company - remaining 90%. 9, 000. Impact
-
Pharma deals in August 2015
Acquisition ‐ company. 1300. Promedior. BMS. PRM 151 recombinant pentraxin‐ 2 protein for idiopathic pulmonary fibrosis and myelofibrosis.
-
Pharma deals during November 2014
Good news at last. Days after finally getting the FDA's go-ahead to resume development of its lead candidate, imetelsta, for myelofibrosis and myelodysplastic syndrome, Geron has signed a deal
-
NICE and ‘ultra orphans’
It won't, for example, affect medicines such as Novartis' treatment for myelofibrosis, a rare blood cancer of which there are only around 0.4 cases of the condition per 100,
-
Pharma deals during November 2013
Pacritinib, an oral therapy, is currently in phase III development for patients with myelofibrosis and has activity against genetic mutations linked to myelofibrosis, leukaemia and certain solid tumours.
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest appointments
-
Boston Biomedical appoints commercial head
At Incyte, she established the company's commercial operations and successfully launched Jakafi (ruxolitinib) for myelofibrosis as part of a collaboration with Novartis.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
THE OTHER SIDE OF...BLOOD CANCER
He just never makes any time for me.”. Meet Sophie. What she suffers from you have probably never heard of: a blood cancer, or neoplasm, called myelofibrosis.
-
THE OTHER SIDE OF...BLOOD CANCER
He just never makes any time for me.”. Meet Sophie. What she suffers from you have probably never heard of: a blood cancer, or neoplasm, called myelofibrosis.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Featured jobs
- Home based, Principal Medical Writer, Medical Communications
-
Excellent package
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
- Account Director, Consumer Healthcare PR, Global PR agency
-
£50, 000 – £58, 000
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Business Unit Head, Medical Communications, London
-
Excellent package
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
- Senior Project Manager - Medical Writing
-
Great salary and bebefits
- Home based, Chief Medical Writer, Medical Communications
-
Excellent package
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Strategic Planner, Healthcare Advertising
-
£47, 000 – £53, 000
-
Senior Account Manager
-
Competitive salary commensurate with experience
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
- Home based, Editorial Team Leader, Medical Communications
-
Excellent package
-
Client Services Director - Med Comms
-
Great salary and bebefits
-
Account Manager
-
£40, 000 - £45, 000 benefits
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
Subscribe to our email news alerts
- Communiqué Awards 2018: Photo Gallery - Communiqué Awards 2016
- GSK sells eczema and psoriasis drug to Dermavant for £250m
- Moving annual total (MAT)
- Roche keeps Venclexta train rolling with new leukaemia filing
- NHS England says yes to Roche's Hemlibra
- Daily Brief: Trump arrives in London, NICE says no to Darzalex, Pfizer backs down on prices
- Huntsworth buys Giant Creative Strategy
- Daily Brief: success for Pfizer and Lilly arthritis drug, Darzalex soars, IMI launches Accelerator
- Brexit rebels win vote on European Medicines Agency alignment
- Data Visualisation
- The True Potential of Mobile Health Tech
- NHS England to Vertex: come clean on Orkambi offer
PMHub
Complete Medical Communications (CMC)
CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...
Latest intelligence
- Developing advocacy in the pharmaceutical industry.
- The importance of advocacy programmes...
- GDPR and events. What does the pharma industry need to know?
- Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
- Digital trends in B2B sales - how far behind is Pharma?
- The modern approach to B2B sales is data-driven, and enabled by digital tools....
Quick links
Infographics
